An exploration of amyloid beta’s action on synaptic transmission has revealed new targets for the treatment of Alzheimer’s Disease.

Prof Nigel Emptage, Department of Pharmacology, University of Oxford
20 March 4.00pm, In person only seminar, venue BSRC Seminar Room

Emptage Group | Synaptic Pharmacology

Disappointing outcomes in clinical trials of amyloid β lowering agents for Alzheimer’s disease (AD) has made the search for alternative molecular targets of critical importance. However, a limited understanding of molecular pathways mediating the effects of amyloid β on synaptic and cognitive function continues to hamper these efforts. We have undertaken an analysis of amyloid β’s action at excitatory synapses and have identified a previously unrecognized mechanism that drives disease progression in AD, and in doing so have identified new, tractable therapeutic targets. The talk will present these data and will reveal that full rescue has been possible in AD model mice.